Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases

Agarwal P, Frucht SJ (2003) Myoclonus. Curr Opin Neurol 16:515–521 Beran RG, Berkovic SF, Black AB et al (2005) Efficacy of levetiracetam 1000–3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open label single-arm study. Epilepsy Res 63:1–9 Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, The Levetiracetam N01057 Study Group (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69:1751–1760 Boeve BF, Lamg AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54:S15–S19 Crest C, Dupont S, Leguern E et al (2004) Levetiracetam in progressive myoclonic epilepsy. An exploratory study in 9 patients. Neurology 62:640–643 D’Amelio M, Callari G, Gammino M et al (2005) Levetiracetam in the treatment of vascular chorea: a case report. Eur J Clin Pharmacol 60:835–836 de Tommaso M, di Fruscolo O, Sciruicchio V et al (2005) Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 28:280–284 Fahn S (2002) Overview, history, and classification of myoclonus. Adv Neurol 89:13–17 Frucht S, Leurgans S, Hallet M et al (2000) The Unified Myoclonus Rating Scale (UMRS): a statistically validated clinical rating instrument for evaluating patients with myoclonus. Mov Disord 15(Suppl 3):107 Grisoli M, Fetoni V, Savoiardo M et al (1995) MRI in corticobasal degeneration. Eur J Neurol 2:547–552 Grosse P, Kühn A, Cordivari C, Brown P (2003) Coherence analysis in the myoclonus of corticobasal degeneration. Mov Disord 18:1345–1350 Keswani SC, Kossoff EH, Krauss GL et al (2002) Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 73:457–458 Kompoliti K, Goetz CG, Boeve BF et al (1998) Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55:957–961 Krauss GL, Bergin MB, Kramer RE et al (2001) Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 56:411–412 Litvan I, Bhatia KP, Burn DJ et al (2003) SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:467–486 Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracteam. Proc Natl Acad Sci USA 101:9861–9866 Lyons KE, Pahwa R (2006) Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 29:148–153 Margineanu DG, Klitgaard H (2000) Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42:281–285 Meco G, Fabrizio E, Epifanio A et al (2006) Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 29:265–268 Mima T, Nagamini T, Ikeda A et al (1998) Pathogenesis of cortical myoclonus studied by magnetoencephalography. Ann Neurol 43:598–607 Riley DE, Lang AE, Lewis A et al (1990) Cortical-basal ganglionic degeneration. Neurology 40:1203–1212 Sawle GV, Brooks DJ, Marsden CD et al (1991) Corticobasal degeneration: a unique pattern of regional cortical oxygen metabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 114:541–556 Shibasaki H, Kuroiwa Y (1975) Electroencephalographic correlates of myoclonus. Electroencephalogr Clin Neurophysiol 36:455–463 Storey E, Lichtenstein M, Desmond P et al (1995) Clinical features and SPECT scanning in presumed corticobasal ganglionic degeneration. J Clin Neurosci 2:321–328 Striano P, Manganelli F, Boccella P et al (2005) Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 20:1610–1614 Thompson PD, Day BL, Rothwell JC et al (1994) The myoclonus in corticobasal degeneration. Brain 117:1197–1207 Wadia PM, Lang AE (2007) The many faces of corticobasal degeneration. Parkinsonism Relat Disord 13:S336–S340 Zesiewicz TA, Louis ED, Sulivan KL et al (2004) Substantial improvement in a Meige’s syndrome patient with levetiracteam treatment. Mov Disord 19:1518–1521